Exenatide Once Weekly + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Children and Adolescent With Type 2 Diabetes
Conditions
Children and Adolescent With Type 2 Diabetes
Trial Timeline
Dec 2, 2011 → May 5, 2021
NCT ID
NCT01554618About Exenatide Once Weekly + Placebo
Exenatide Once Weekly + Placebo is a phase 3 stage product being developed by AstraZeneca for Children and Adolescent With Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01554618. Target conditions include Children and Adolescent With Type 2 Diabetes.
What happened to similar drugs?
0 of 12 similar drugs in Children and Adolescent With Type 2 Diabetes were approved
Approved (0) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01554618 | Phase 3 | Completed |
| NCT01144338 | Phase 3 | Completed |
Competing Products
20 competing products in Children and Adolescent With Type 2 Diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Quizartinib + Etoposide + Dexrazoxane + Mitoxantrone + Cytarabine + Methotrexate + Daunorubicin + Fludarabine | Daiichi Sankyo | Phase 2 | 42 |
| RSS0393 Ointment | Jiangsu Hengrui Medicine | Phase 2 | 42 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 21 |
| MEDI3250 + Placebo | AstraZeneca | Phase 3 | 40 |
| MEDI3250 | AstraZeneca | Phase 3 | 40 |
| Budesonide Formoterol Drug Combination + nebulisation of terbutaline | AstraZeneca | Phase 3 | 32 |
| Saizen® A + Saizen® B | Merck | Phase 3 | 40 |
| zolinza/vorinostat | Merck | Phase 1/2 | 32 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 40 |
| Hydroxyurea | Novartis | Phase 3 | 47 |
| Norditropin® FlexPro® | Novo Nordisk | Pre-clinical | 33 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 40 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 39 |
| somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 40 |
| Somapacitan | Novo Nordisk | Pre-clinical | 33 |
| Voxelotor | Pfizer | Phase 2 | 27 |
| Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citrate | Pfizer | Phase 3 | 40 |
| Copanlisib (BAY806946) | Bayer | Phase 1/2 | 21 |
| Eptinezumab | Lundbeck | Phase 1 | 26 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |